We thus identified that among the 85 severe/critical COVID-19 patients, 10 patients (11.8%, 95% CI [6.5–20.3]) had plasma-neutralizing antibodies against IFN-α2 and/or IFN-ω. Here, IFNA2 is linked to COVID-19.